Bio-Rad Laboratories, Inc. (BIO)

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
United States Revenue	1.01B	1.02B	1.04B
United States Revenue Growth	-1.16%	-1.80%	-7.17%
EMEA Revenue	888.80M	881.80M	834.10M
EMEA Revenue Growth	0.79%	5.72%	1.74%
APAC Revenue	519.60M	513.30M	521.60M
APAC Revenue Growth	1.23%	-1.59%	-7.35%
Other Regional Revenue	170.70M	165.40M	169.30M
Other Regional Revenue Growth	3.20%	-2.30%	1.68%
Revenue (Total)	2.59B	2.58B	2.57B
Revenue (Total) Growth	0.26%	0.65%	-3.92%

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Life Science Revenue	1.02B	1.02B	1.03B
Life Science Revenue Growth	-0.01%	-0.68%	-12.75%
Clinical Diagnostics Revenue	1.57B	1.56B	1.54B
Clinical Diagnostics Revenue Growth	0.43%	1.57%	3.26%
Other Segments Revenue	-	-	500.00K
Other Segments Revenue Growth	-	-	-85.71%
Revenue (Total)	2.59B	2.58B	2.57B
Revenue (Total) Growth	0.26%	0.65%	-3.92%

Gross Profit

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Life Science Segment Profit	552.30M	553.10M	582.40M
Life Science Segment Profit Growth	-0.14%	-5.03%	-12.29%
Clinical Diagnostics Segment Profit	791.00M	786.80M	796.60M
Clinical Diagnostics Segment Profit Growth	0.53%	-1.23%	4.33%
Other Segments Segment Profit	-	-	-100.00K
Gross Profit (Total)	1.34B	1.34B	1.38B
Gross Profit (Total) Growth	0.25%	-2.83%	-3.36%

Data Source: Fiscal.ai Last updated: Apr 30, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 23, 2026

Data Sources Report a data error